Pharmaceutical

Grifols gears up for FDA approval of fibrinogen replacement therapy

Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans to file for approval in Q4 2024.

Feb 14, 2024 - 18:00
Grifols gears up for FDA approval of fibrinogen replacement therapy
Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans to file for approval in Q4 2024.
Read the original article

Tags:

Previous Article

BMS signs $674m GenAI drug discovery deal with VantAI

Next Article

Sudo secures additional funds to advance TYK2 inhibitors to clinic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ligand Pharmaceuticals to acquire APEIRON Biologics for $100m

Ligand Pharmaceuticals to acquire APEIRON Biologics for...

Jul 10, 2024

STAT+: Novo Nordisk is concluding research on Wegovy’s impact on osteoarthritis

STAT+: Novo Nordisk is concluding research on Wegovy’s ...

Nov 5, 2023

STAT+: U.K., pharma industry strike deal for how the NHS pays for medicines

STAT+: U.K., pharma industry strike deal for how the NH...

Nov 21, 2023